Vulvar cancer Lymph nodes HPV Vulvacarcinoom Lymfeklieren HPV
Conditions
Interventions
Patients who will undergo a lymphadenectomy will be asked to participate in detecting the SLNs prior to the lymph node dissection by injecting patent blue in the tumour margins before the (local) exci
Sponsors
NKI-AVL
Eligibility
Inclusion criteria
Inclusion criteria: - Age ≥ 18 years at start of the study; - Primary carcinoma of the vulva with an indication for sentinel node procedure or inguinofemoral lymphadenectomy; - Operation at the NKI-AVL or AMC/VUmc; - Signed informed consent.
Exclusion criteria
Exclusion criteria: - Patiënts who had previous therapy for macro invasive vulvar cancer (including sentinel node procedure) will not participate in the sentinel node part of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To analyse the microenvironment of (S)LNs and PT (i.e. various T-cell populations, antigen presenting cells and myeloid suppressor cells) and other immune factors produced by the tumour cells in patients with vulvar cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| - to assess the differences of the microenvironment in HPV-positive and HPV-negative (S)LNs - to assess the difference of the microenvironment of tumour-negative and metastatic (S)LNs. - to assess the difference of the microenvironment of SLNs and non-SLNs. Exploratory objectives: - to analyse the difference in the (S)LNs compared to the PT. | — |
Contacts
Public ContactJossie Rotman
VUmc-Cancer Center Amsterdam, CCA 2 - 48
Outcome results
None listed